Roche

Covid-19 development round-up: March 4, 2022

The state of the fight: 

Pfizer/BioNTech’s Comirnaty appeared to offer only 12% effectiveness against Omicron in children ages 5-11.
  South Africa’s Biovac partnered with nine development institutions to boost local vaccine manufacturing capacity.
  Eli Lilly’s arthritis drug Olumiant reduced the risk of death by 13% in hospitalized Covid-19 patients.   AUTHORIZED VACCINES

 
Pfizer/BioNTech’s Comirnaty is far less protective against infection in children ages…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, Novavax, Sinovac, Valneva, FDA, Bharat Biotech, Inovio, Shionogi, CureVac, GSK, Biovac, Gamaleya Institute, WHO, MPP, Moderna, Bio Farma, ACT-A, EMA, J&J, AstraZeneca, Merck, Regeneron, Roche, Lilly, Gilead, DNDi
Read more
More pharma companies post Q4 and full-year 2021 financials

Fourteen leading pharma companies released fourth-quarter and full-year 2021 financial results in February. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the pack, SK Bioscience generated an unprecedented $375 million in fourth-quarter revenues—a 573% jump from the same period in 2020—driven by its CMO drug substance manufacturing business, which contributed to AstraZeneca/Oxford and Novavax Covid-19 vaccine production. The South Korean company also…

Mentions:
SK Bioscience, Pfizer, AstraZeneca, Merck, LG Chem, Novo Nordisk, Sanofi, Roche, BMS, Eli Lilly, Novartis, Gilead, Viatris, Teva, financials
Read more
Covid-19 development round-up: February 18, 2022

The state of the fight: 

Moderna applied for South African patents on its vaccine, potentially jeopardizing the work of the WHO-led mRNA vaccine “hub” operating in the country.
  WHO named five additional African countries that will receive vaccine technology from the hub.
  Laboratorios Farmacéuticos Rovi inked a 10-year mRNA vaccine manufacturing extension with Moderna.   AUTHORIZED VACCINES

                                       
Medigen’s protein subunit…

Mentions:
Covid-19, vaccines, drugs, Medigen, AstraZeneca, Biological E, Moderna, Novavax, Abogen, Walvax, Gamaleya Institute, WHO, Afrigen, Pfizer, BioNTech, COVAX, Gavi, Merck, Gilead, Roche, Shionogi
Read more
Covid-19 development round-up: February 11, 2022

The state of the fight: 

A Lilly mAb active against Omicron won a U.S. FDA emergency use nod.
  Novavax’s shot proved 80% efficacious in adolescents ages 12-17, according to a Phase 3 readout.
  Vaxxinity’s UB-612 vaccine candidate performed better against Omicron than an mRNA-based comparator jab.

 

AUTHORIZED VACCINES

 
J&J’s single-dose shot was only 53% efficacious against moderate to severe Covid-19 (28 days post-injection) in a final analysis…

Mentions:
Covid-19, vaccines, drugs, J&J, Novavax, FDA, Pfizer, BioNTech, Bharat Biotech, CNBG, Sinopharm, Gamaleya Institute, Sinovac, EMA, AstraZeneca, Walvax, Moderna, Biological E, African Union, COVAX, WHO, ACT-A, Lilly, Gilead, Merck, GSK, Vir, Regeneron, Roche, DNDi, Novartis
Read more
Pfizer poaches Roche R&D chief

Pfizer has named William Pao to succeed Rod MacKenzie as its chief development officer, the multinational announced Tuesday. Pao joins from Roche, where he's overseen research and development since 2018.

MacKenzie is retiring after 35 years at Pfizer, per the company's press release.

Mentions:
leadership, R&D, Pfizer, Roche
Read more
Covid-19 development round-up: January 28, 2022

The state of the fight: 

Moderna and Pfizer/BioNTech launched trials of Omicron-specific vaccine candidates.
  India fully approved SII’s Covishield and Bharat Biotech’s Covaxin shots.
  CEPI tapped BioNet to develop a “variant-proof” pan-coronavirus mRNA-based vaccine.

AUTHORIZED VACCINES  

New data on rates of myocarditis following mRNA-based vaccination trickled in this week, highlighting an increased risk of the heart inflammation side effect in young men…

Mentions:
Covid-19, vaccines, drugs, SII, BBIL, Pfizer, BioNTech, Moderna, J&J, Sinovac, CanSino, AstraZeneca, EMA, FDA, Sanofi, GSK, Novavax, Zydus Cadila, CEPI, COVAX, Gavi, MPP, Merck, Lilly, Regeneron, Roche, Gilead
Read more
Covid-19 development round-up: January 21, 2022

The state of the fight: 

African vaccine production advanced on multiple fronts, including the opening of a new manufacturing plant in South Africa.
  The COVAX AMC seeks an additional $5.2 billion this year.
  Merck will supply UNICEF with up to 3 million courses of molnupiravir in the first half of 2022.

AUTHORIZED VACCINES  

The Chilean health ministry released data on the Sinovac jab’s effectiveness in children. In kids ages 6-11, the topline numbers…

Mentions:
Covid-19, vaccines, drugs, WHO, Pfizer, BioNTech, Sinovac, EMA, Moderna, J&J, SII, BBIL, Novavax, Gamaleya Institute, Valneva, Clover, CEPI, IPD, COVAX, Gavi, Merck, UNICEF, MPP, GSK, Vir, Gilead, Regeneron, Roche
Read more
Covid-19 development round-up: January 14, 2022

The state of the fight: 

A booster dose of Bharat Biotech’s Covaxin increased neutralizing antibodies up to 265-fold.
  WHO added therapies from Eli Lilly and GSK/Vir to its list of recommended Covid-19 treatments.
  Novartis will pay over $162 million to in-license Molecular Partners’ ensovibep antiviral candidate.

 

AUTHORIZED VACCINES

Two doses of Pfizer/BioNTech’s vaccine reduced the risk of Covid-19 hospitalization by 94% among adolescents ages 12…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, AstraZeneca, Moderna, J&J, Janssen, FDA, EMA, BBIL, Novavax, SII, WHO, Sinovac, CanSino, COVAX, UNICEF, Lilly, GSK, Vir, Regeneron, Roche, Merck, Novartis
Read more
Covid-19 development round-up: January 7, 2022

The state of the fight: 

India granted Biological E’s Corbevax—a low-cost, patent-free vaccine—its first regulatory authorization.
  A J&J booster was 85% effective against hospitalization in South Africa during the Omicron wave.
  India authorized molnupiravir but omitted the antiviral from its recommended clinical protocol on safety concerns.

 

AUTHORIZED VACCINES

 
Bharat Biotech’s Covaxin generated “superior antibody responses” in children…

Mentions:
Covid-19, vaccines, drugs, BBIL, Pfizer, BioNTech, AstraZeneca, J&J, Janssen, CanSino, CDC, Bio E, Novavax, FDA, SII, CNBG, Sinopharm, Moderna, Gamaleya Institute, Sinovac, SK Bioscience, CEPI, GSK, Vir, Merck, Regeneron, Roche, Gilead, Shionogi
Read more
Covid-19 development round-up: December 17, 2021

The state of the fight: 

WHO issued an Emergency Use Listing for Serum Institute of India’s version of Novavax’s vaccine.
  The U.S. CDC recommended mRNA-based vaccines over J&J’s.
  Data on the effectiveness of monoclonal antibody therapies against the Omicron variant began pouring in.

AUTHORIZED VACCINES  

A U.S. CDC advisory panel recommended mRNA-based vaccines over the J&J jab, citing blood clot side effects stemming from the single-dose…

Mentions:
Covid-19, vaccines, drugs, Moderna, NIH, J&J, Janssen, Pfizer, BioNTech, CanSino, SII, Novavax, WHO, EMA, COVAX, FDA, Takeda, Butantan Institute, Sinovac, BBIL, Sanofi, GSK, AstraZeneca, Valneva, CNBG, Sinopharm, Gamaleya Institute, Gavi, CEPI, Merck, Regeneron, Roche, Lilly, Vir, Novartis
Read more
Subscribe to Roche